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Abstract
Background: KBH-1 is an herbal mixture of Saururus chinensis, Curcuma longa and Polygala tenuifolia. Each herb has
been reported to have various pharmaceutical activities; however, the synergistic effect of this herbal composition
on obesity has not yet been determined. We investigated the alleviation effect of KBH-1 and its possible molecular
mechanism in obesity-induced hepatic steatosis and leptin resistance in the hypothalamus.
Methods: We used HepG2 cells, primary neuronal cells and a high-fat diet (HFD)-induced obesity rat model to
determine the effect of KBH-1 in vitro and in vivo on hepatic steatosis and leptin resistance accompanied by
obesity. To identify the alleviation effect on lipid accumulation, HepG2 cells stimulated by FFA were stained with Oil
Red O; in addition, immunoblotting and qPCR were performed to determine the effect of KBH-1 on the activation
of proteins and nuclear enzymes in HepG2 cells and the steatotic liver of HFD-induced obesity rats. To examine the
effect of KBH-1 on the leptin resistance of the hypothalamus and its possible molecular mechanism, we examined
the effect of KBH-1 on the activation of the leptin resistance-related protein in primary cultured cortical neuron cells
and the hypothalamus of an HFD-induced obesity rat model. In addition, we used HPLC analysis to identify the
standard compound of KBH-1.
Results: KBH-1 not only suppressed the lipid deposition in HepG2 cells exposed to free fatty acids (FFA) but also
significantly down-regulated major factors in lipogenesis and up-regulated major factors in lipolysis. Similarly, in a
HFD-induced obesity model, KBH-1 improved hepatic steatosis by alleviating the effects on lipogenic genes and
kinases. In addition, KBH-1 significantly improved the leptin-mediated signals impaired by obesity or FFA in the
obesity model and primary cultured cortical neuron cells. In addition, KBH-1 was analyzed to include six standard
compounds using HPLC analysis, among these compounds, onji-saponin B and curcumin were potently suppressed
the level of triglycerides.
Conclusions: KBH-1 exhibits alleviating effects by improving hepatic steatosis and leptin resistance by up-regulating
the activation of AMPK and suppressing the expression of PPARγ. These findings show the potential of KBH-1 as a
functional food supplement or preventive agent in the treatment of obesity.
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Background
Hepatic steatosis, a type of non-alcoholic fatty liver disease
(NAFLD), is a general form of chronic liver disease and is
caused by peripheral responses associated with obesity [1].
The main symptom of NAFLD is the accumulation of tri-
glycerides (TG) and accompanying steatosis and obesity
through leptin resistance as the pathological status in
clinics [2]. Leptin, an adipose-derived hormone, is known
to act on the hypothalamus of the brain to reduce food in-
take and increase energy spending by circulating at levels
according to body fat mass [3]. Obesity enhances the lep-
tin level by increasing adiposity and up-regulating enzyme
expression, including β-oxidation and mitochondrial un-
coupling, to dissipate the excess of energy. In previous
studies, a diet-induced animal model is invariably accom-
panied by hyperleptinemia, and long-lasting hyperleptine-
mia causes the failure of appetite modulation by leptin
resistance in the hypothalamus [4]. Finally, leptin has a
critical role in modulating energy balance and anorexi-
genic hormones in the hypothalamus of the brain. Leptin
acts by binding to a specific receptor, which has been
identified as six isoforms of LepRa through LepRf [5].
Among the isoforms of leptin receptors, LepRb mediates
most of the biological effects of leptin through the phos-
phorylation of both Janus kinase (JAK) 2 and signal trans-
ducer and activator of transcription (STAT) 3. The
activation of JAK2 leads to the phosphorylation of tyrosine
residues located in the intracellular domain of the LepRb,
such as Tyr 985, Tyr 1077, and Tyr 1138 [6]. The phos-
phorylation of each tyrosine residue mediates the activa-
tion of extracellular signal-regulated kinase (ERK), STAT3,
and STAT5, which leads to the increased transcription
and expression of suppressors of cytokine signaling
(SOCS) 3. SOCS3, which acts as an inhibitor by attenuat-
ing LepRb signaling, plays a central role in leptin resist-
ance [6]. In addition, recent reports have suggested that
leptin may act directly on the liver by influencing the lep-
tin signaling and insulin signaling pathway and affecting
hepatic lipid and lipoprotein metabolism [7]. Leptin acts
mainly by activating the JAK3/STAT3 signaling in hepatic
cells and results in the activation of phosphatidylinositol-3
kinase (PI3K)/AKT [8]. However, the pathway of 5-
adenosine monophosphate-activated protein kinase
(AMPK) and forkhead box protein (FOX) O1 was re-
ported to be associated with leptin signaling, although
their role in hepatic cells is not fully clear [9]. Therefore,
the present study aimed to determine the modulation of
leptin signaling molecule during the development of hep-
atic steatosis by a high-fat diet (HFD)-induced obesity
model. In addition, the aim of this study is to identify
the effect of KBH-1, standardized herbal composition,
on steatosis and leptin resistance.
KBH-1, a novel herbal mixture, consists of Chinese
lizard’s tail (Saururus chinensis), turmeric (Curcuma
longa) and Chinese senega (Polygala tenuifolia). These
herbs have been used as traditional Korean medicine
in different countries, including China and southern
Korea, for various purposes, and they have various
pharmaceutical activities, such as anti-obesity effects,
anti-inflammatory effects, anti-oxidative effects, neu-
roprotective effects, and the prevention of hyperchol-
esterolemia [10–16]. Saururus chinensis has been used
in folk medicine for the treatment of various inflam-
matory diseases, gonorrhea, and edema in Korea [17]
and exhibits anti-asthmatic and anti-inflammatory ac-
tivities [18]. In addition, previous biological studies of
Saururus chinensis have established its effects in
metabolic diseases, including hyperlipidemia, hyper-
glycemia, neuroprotective, and hepatoprotective ef-
fects [19–23]. Curcuma longa has been used in
traditional medicine in China, Korea and India for
ages as the main ingredient in prescriptions, such as
Xiaoyao-san for mental disorders [24]. In addition,
this extract has been used for the treatment of blood
stasis in traditional Korean medicine [25]. Moreover,
Curcuma longa is a main ingredient in Gambigyeong-
sinhwan, exerts an anti-obesity effect through lipid
accumulation and adipose PPARα activation [26] and
prevents high-fat diet-induced hyperlipidemia as a
main ingredient in Artemisia iwayomogi [27]. Polygala
tenuifolia has been used as a traditional Chinese
medicine for the treatment of anxiety and dementia
[28, 29], and the preventive effects of this extract on
behavior disorders and inflammatory diseases have
been demonstrated [30, 31].
The synergistic effect of Saururus chinensis, Curcuma
longa and Polygala tenuifolia extracts on the complica-
tions that accompany obesity has not yet been deter-
mined. Therefore, as a preliminary study, we confirmed
the efficacy of KBH-1 compared with each ingredient in
the lipid accumulation of HepG2 cells (Additional file 1:
Table S1). Therefore, in this study, the effects of KBH-1
in hepatic steatosis and leptin resistance in the hypothal-
amus were investigated, as was its possible molecular
mechanism of action. Our results provide experimental




Polygala tenuifolia Willdenow (China), Curcuma longa
Linne (China) and Saururus chinensis Baill (Korea) were
obtained from Yeongcheon Oriental Herbal Market
(Yeongcheon, Korea). The identification of all plant ma-
terials was confirmed by Dr. Ki Hwan Bae of the College
of Pharmacy, Chungnam National University (Daejeon,
Korea). HepG2 cells were obtained from the American
Type Culture Collection (Manassas, VA, USA). Oleic
Lee et al. BMC Complementary and Alternative Medicine  (2016) 16:355 Page 2 of 12
acid, palmitic aid, leptin, L-glutamine, polyethylenimine
(PEI), D-glucose, and Oil Red O were obtained from
Sigma Chemical (St. Louis, MO, USA). Fetal bovine
serum, 100 U/ml penicillin/10 μg/ml streptomycin, Dul-
becco's Modified Eagle Medium: Nutrient Mixture F-12
(DMEM/F12), Neurobasal Medium, B27, and L-glutamine
were purchased from Gibco (Carlsbad, CA, USA). Adi-
poRed was obtained from Lonza (Walkersville, MD, USA).
Hank’s Balanced Salt Solution (HBSS) was purchased from
WELGENE (Gyeongsan-si, Korea). The anti-ERK1/2
(Thr202/Tyr204), phosphospecific ERK1/2 (p44/p42),
anti-acetyl-CoA carboxylase (ACC), phosphospecific ACC
(Ser79), phosphospecific STAT3 (Tyr 705), anti-AKT,
phosphospecific AKT (Ser473), anti-AMPK, phosphospe-
cific AMPK (Thr172), anti-RAS, phosphospecific c-Raf
(Ser289/296/301), and anti-tubulin were obtained from
Cell Signaling Technology, Inc. (Boston, MA, USA). The
anti-leptin receptor was purchased from Abcam (Cam-
bridge, UK). The anti-JAK2, phosphospecific JAK2
(Tyr1007/1008), and anti-beta-actin were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Secondary
antibodies for immunoblot analysis, the ECL kit and the
BCA protein assay kit were purchased from Thermo
(Rockford, IL, USA). The PVDF membrane was purchased
from Millipore (Darmstadt, Germany). The RNA extrac-
tion kit was obtained from Ambion (Austin, TX, USA).
AccuPower RT PreMix, AccuPower GreenStar qPCR
Master Mix and primers were purchased from Bioneer
(Daejeon, Korea). Taqman gene expression assays and
gene expression master mix were obtained from Applied
Biosystems (ABI; NY, USA). The 10 % and 45 % kcal high-
fat diets were purchased from Research Diet, Inc. (New
Brunswick, USA). The green tea extract was purchased
from Amax NutraSource, Inc. (Eugene, OR, USA). The
leptin ELISA kit was purchased from MIoBs (Yokohama,
Japan). The free fatty acid assay kit and thiobarbituric Acid
Reactive Substances (TBARs) assay kit were purchased
from Bioassay System (Hayward, CA, USA). The CCK-8 kit
was obtained from Dojindo Molecular Technologies (Rock-
ville, MD, USA). The GOT, GPT and TG, T-C assay kit
were obtained from Asan Pharmaceutical (Seoul, Korea).
Preparation of KBH-1
KBH-1 was composed of the same quantities of Polygala
tenuifolia, Curcuma longa Rhizoma and Saururus chi-
nensis as previously described [32]. Briefly, all voucher
specimens were deposited in the herbal Bank of the
KM-Based Herbal Drug Research Group, Korea Institute
of Oriental Medicine. The three herb mixture were
added to 60 % ethanol of ten times as primary extraction
and five times as secondary extraction and then ex-
tracted by heating at 70-75 °C two times (3 h and 2 h)
using COSMOS-660 (KYUNGSEO MACHINE Co, In-
cheon Korea). After extraction, the obtained KBH-1
extract was filtered out using Nylon 50 μm and concen-
trated using the Laborota 20 (Heidolph Ins., Germany)
until 20-35 brix. The dextrin was added to the concen-
trate and prepared into powder by a spray dryer. The
yield rate was 19 %.
High performance liquid chromatography (HPLC) analysis
Using HPLC analysis, KBH-1 and its standard reference
compounds, including quercitrin, onji-saponin B, bis-
demethoxycurcumin (BDMC), demethoxycurcumin
(DMC), curcumin and sauchinone, were standardized
for quality control. Each standard stock was prepared by
dissolving four standard compounds at 1 mg/mL in 100
% methanol. Sample stock solution was extracted at 10
mg/mL in 100 % methanol, which was sonicated at room
temperature for 30 min. All standards and sample solu-
tion were filtered through a 0.22 μm syringe membrane
filter from Whatman Ltd (Maidstone, UK) and stored at
4 °C before analysis. Chromatographic analysis of a
reverse-phase HPLC system (Dionex Co., CA, USA) was
performed with an ultimate diode array detector (DAD),
injector 10 μL sample loop (Dionex, ID × L = 0.18 × 550
mm, Viper 550 mm, USA), ultimate 3000 pump and
Chromeleon data acquisition system (Dionex, version 7,
USA). Separation using an Optimapak C18 RP-column
(250 × 4.6 mm, 5 μm, C18, Korea) was performed at 40 °C.
The gradient elution was used with the following solvent
systems: mobile phase A: double distilled water/triflouroa-
cetic acid (TFA) (99.9/0.1; v/v), mobile phase B: aceto-
nitrile. The run time of this system was 60 min, and the
linear gradient method was applied to the mobile phase
condition (solvent A: 90–30 %, B: 10–70 %, flow rate: 1.0
mL/min). The elution was performed with a gradient pro-
cedure as follows: 0–60 min, 2 % B; 2–60 min, from 2 % B
to 98 % B.
HepG2 cell culture and free fatty acid (FFA) treatment
Cells of the hepatocellular carcinoma cell line HepG2
were routinely cultured in DMEM/F12 supplemented
with 10 % fetal bovine serum and 100 U/ml penicillin/
streptomycin 10 μg/ml at 37 °C in a humidified atmos-
phere with 5 % CO2 in an incubator as previously de-
scribed [33, 34]. The cells were grown to 75-80%
confluence and then starved in serum-free medium
overnight before treatment. For treatment experiments,
the cells were treated with KBH-1 at 10, 30 and 90 μg/ml
concentrations for 6 h and then exposed to a mixture of
FFA (oleic acid/palmitic acid at 2:1) at a final concentra-
tion of 1 mM for 24 h. Fat droplets in cells were stained
with Oil Red O dye. For Oil Red O staining, cells were
fixed with 4 % neutral formaldehyde solution and stained
with filtered Oil Red O solution for 15 min. After staining
the lipid droplets, the staining solution was removed, and
the plates were rinsed with water and photographs were
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taken using a Nikon digital camera system. To measure
the intracellular triglyceride content, HepG2 cells were
washed and incubated with the Adipored and then sub-
jected to a Spectra Mas M2 fluorescence spectrophotom-
eter (Molecular Devices, Sunnyvale, CA, USA) by the
Adipored kit according to the manufacturer’s protocol.
Cytotoxicity was tested using the Cell Counting Kit-8 ac-
cording to the recommended methods.
Primary neuronal cell culture and leptin resistance
Neuronal cells were primary cultured as described previ-
ously [35]. For primary cortical neuron cultures, the em-
bryonic rat cortex was established from the 18-day
embryos of SD rats (Samtako Bio Korea, Osan, Gyeong-
gido, Korea). Briefly, the cortex was removed and incu-
bated for 15 min in HBSS containing 2 mg/ml trypsin.
Cells were then dissociated by trituration and plated
(5 × 106 cells/ml) into PEI-coated plastic culture dishes
containing Neurobasal Medium supplemented with 2 %
B27, 0.5 mM L-glutamine, and 25 μM glutamate. Fol-
lowing cell attachment (24 h post-plating), the culture
medium was replaced with Neurobasal Medium without
glutamate. Experiments were performed using 7- to 9-
day-old cultures. FFA can induce leptin resistance as de-
scribed previously [36]. To detect leptin signaling, pri-
mary neurons were pretreated with 0.5 mM FFA
(FFA;oleic acid:palmitic acid = 2:1) overnight prior to
leptin treatment. For treatment studies, neurons were
treated with KBH-1 for 1 h and then cotreated with 10
nM leptin as described previously [37]
RNA isolation and RT-PCR
Total cellular RNA was extracted using TRIzol reagent ac-
cording to the recommended methods. The quantity of
isolated RNA was measured using a NanoDrop spectro-
photometer (Thermo Scientific, Ltd., Waltham, MA) and
processed for cDNA synthesis using the AccuPower RT
PreMix cDNA synthesis kit according to the manufac-
turer’s protocol. Subsequently, SYBR Green-based qPCR
amplification was performed using cDNA (extracted from
HepG2 cells), 10 pmol of primers and AccuPower Green-
Star qPCR Master Mix in the Applied QuantStudio 6 real-
time PCR system (LifeScience, Carlsbad, CA USA) according
to the instruction manual. The primer sequences for
PCR analysis were as follows: CD36 (reverse) TTGAT
TTTGATAGATATGGGATGC, (forward) TGGAACAGA
GGCTGACAACTT; SREBP1c (reverse) GGAAGGCTTC
AAGAGAGGAGC, (forward) CGACATCGAAGACATG
CTTCAG; SCD-1 (reverse) GCAGCCGAGCTTTGTAA
GAGCGGT, (forward) CCTCTACTTGGAAGACGACAT
TCGC; ACC1 (reverse) TTCTGCTATCAGTCTGTCCA
G, (forward) GCTGCTCGGATCACTAGTGAA; ACOX1
(reverse) CCACAGGACACCATTAAGC, (forward) GCG
GACTACACTTCATAAATGC, CPT-1 (reverse) GGAG
TGACCGTGAACTGAAAG, (forward) CCTCCGTAGC
TGACTCGGTA; PPAR α (reverse) GGGAACAGATTTC
CACATTG, (forward) TGGCTCTTGACCCTATTGG; beta-
actin (reverse) TCGGCCACATTGTGAACTTT, (forward)
TGGATCAGCAAGCAGGAGTA. Taqman probe–based
qPCR amplification was performed using cDNA (extracted
from animal organ), inventoried TaqMan gene expression
assays and TaqMan Gene Expression Master Mix in the
Applied QuantStudio 6 real-time PCR system according to
the instruction manual. The inventoried probe assay ID for
gene expression was as follows: Hmgcr, rCG44692
(Rn00565598_m1); Srebf1, rCG32702 (Rn01495769_m1);
Cd36, rCG24451 (Rn01442639_m1); Actb, rCG42822
(Rn00667869_m1); Pparg, rCG29795 (Rn00440945_m1);
Cpt1a, rCG48591 (Rn00580702_m1); Fasn, rCG33632
(Rn01463550_m1). The gene expression data were analyzed
using the 2-(ave.△△CT) method as described previously [38].
Protein extraction and western blotting
Immunoblotting was performed as described previously
[39, 40]. Samples were lysed in RIPA buffer consisting of
50 mM Tris-HCl (pH 8.0), 5 mM EDTA, 150 mM NaCl,
1 % NP-40, 0.1 % SDS, 1 mM PMSF, protease-inhibitor
cocktail tablet, and phosphatase-inhibitor cocktail tablet.
Cell lysates were centrifuged at 13,000 rpm for 30 min
at 4°C. The protein concentration was determined using
a BCA Protein Assay Kit. Protein samples were mixed
with sample buffer (100 mM Tris-HCl [pH 7.6], 2 %
SDS, 1 % 2-mercaptoethanol, 2 % glycerol, and 0.01 %
bromophenol blue), incubated at 97 °C for 5 min. Ap-
proximately 15 μg of protein extract was loaded onto 4-
20 % polyacrylamide gels. Electrophoresis was performed
using a Mini Protein 3 Cell kit (Bio-Rad, Hercules, CA,
USA). Resolved proteins were transferred onto a PVDF
membrane. The membrane was first incubated in block-
ing buffer (10 mM Tris-HCl [pH 7.5], 150 mM NaCl,
0.1 % Tween 20, and 3 % BSA) and then incubated over-
night at 4°C with 1000 diluted primary antibodies. After
washing with a washing buffer (10 mM Tris-HCl [pH
7.5], 150 mM NaCl, and 0.1 % Tween 20) three times
for 20 min each, the membrane was probed with
5000 diluted secondary antibody for 1 h at room
temperature. The membrane was then washed with
washing buffer three times for 10 min each and de-
veloped using an ECL kit. Chemiluminescent signals
were detected using a LAS-4000 Luminescent Image
Analyzer (Fuji Photo Film Co., Japan). Band inten-
sities were quantified using ImageJ software (National
Institutes of Health, USA).
High-fat diet (HFD)-induced obesity rat model
All animal experiments were performed according to the
Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health (NIH publication No.
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83-23, revised 1996) and were approved by the Institu-
tional Animal Care and Use Committee of KIOM (Ap-
proval No. 14-027). Male SD rats were purchased from
Samtako Co. (Osan, Korea). All animals were housed in
a room with controlled temperature (20-24 °C), humidity
(40-60 %) and lighting (12 h light/dark cycle) and were
supplied with water ad libitum. After acclimation for 1
week, animals were randomly divided into 2 groups: the
normal group was fed with a 10 % kcal fat diet (ND),
whereas the obesity model group was fed with a 45 %
kcal fat diet (HFD). After 7 weeks of feeding with the
HFD, the resultant obese rats in the HFD group were
subdivided into 4 groups: (1) HFD: 45 % kcal fat diet-fed
rats; (2) PC: HFD treated with 200 mg/kg body weight/
day of green tea extract (PC) administration; (3) KBH-1
150: HFD treated with 150 mg/kg body weight/day of
KBH-1 extract administration; and (4) KBH-1 300: HFD
treated with 300 mg/kg body weight/day of KBH-1 ex-
tract administration. Then, drugs were orally adminis-
tered as a suspension in saline for 8 weeks with a HFD
diet (KBH-1 150 and KBH 300 groups). The same
amount of saline was orally administered to the ND and
HFD groups for 8 weeks with feeding ND or HFD diet
(ND and HFD groups). At the end of the experimental
period, animals were anesthetized by CO2 gas, blood
was collected, and organs were excised. The organs were
rinsed with saline solution, weighed and stored at -80 °C.
Measurement of biochemical parameters and oxidative
stress
Serum total cholesterol (T-C), low density lipoprotein-
cholesterol (LDL-C), high density lipoprotein-cholesterol
(HDL-C), triglyceride (TG), glucose, glutamic-oxaloacetic
transaminase (GOT), glutamic pyruvic transaminase
(GPT), lactate dehydrogenase (LDH), UREA, creatinine
and alkaline phosphatase (ALP) levels were measured
using an Erba XL-200 automated clinical chemistry
analyzer (Mannheim, Germany). Serum leptin, TNFα and
IL-1β levels were measured with a commercial ELISA kit
according to the manufacturer’s protocol. Markers of oxi-
dative stress, such as malondialdehyde (MDA), were mea-
sured with commercial TBARs assay kit according to the
manufacturer’s instructions.
Hepatic lipid extraction and measurement
Hepatic lipid extraction was performed as previously
described [39]. Wet livers (100 mg each) were ho-
mogenized in 0.5 ml of 1 M NaCl. For lipid extrac-
tion, 3 ml of chloroform/methanol (2:1) was added
to 0.5 ml of liver tissue homogenate and vortexed
for 2 h. Then, the mixture was centrifuged at low
speed, and the lipid-containing phase was collected,
dried and re-suspended in 0.5 ml of Triton X-100/
methanol (2:1). TG and T-C were measured with a
commercial assay kit according to the manufacturer's
protocol.
Histological analysis
Gonadal adipose and liver tissues were fixed in 4 % neu-
tral formaldehyde solution. Adipose tissue and liver tis-
sue were subsequently dehydrated in a graded ethanol
series (70-100 %) and embedded in paraffin. The tissues
were sectioned (4 μm thick) using a Leica RM 2165 ro-
tary microtome (Wetzlar, Germany) and stained with
hematoxylin and eosin (H&E). Sections were viewed
with an Axioskop 40 (Oberkochen, Germany) and
photographed at 100× magnification.
Statistical analysis
The data are presented as the mean ± the standard error
of the mean (SEM) and analyzed by GraphPad Prism soft-
ware. An unpaired one-way ANOVA was used as indi-
cated, followed by Dunnet’s test to ascertain statistical
significance.
Results
KBH-1 alleviates free fatty acid-stimulated lipid deposition
and the activation of lipogenic enzymes in HepG2 cells
To investigate the alleviation effect of KBH-1 extract on the
lipid accumulation of HepG2 cells, Oil Red O staining was
performed with KBH-1 at a concentration of 30 μg/ml de-
creased lipid accumulation in HepG2 stimulated by FFA
(Fig. 1a). Therefore, to identify the effect of KBH-1 on the
activation of proteins and nuclear enzymes of HepG2 cells
exposed to FFA, we examined the mRNA level of sterol
regulatory element-binding protein (SREBP)-1c, stearoyl-
CoA (SCD)-1, CD36, acetyl-CoA carboxylase (ACC), acyl-
CoA oxidase (ACOX) 1, carnitine palmitoyltransferase
(CPT)-1 and peroxisome proliferator-activated receptor
(PPAR) α. As shown in Fig. 1b, the expression level of
SREBP-1c, SCD-1, CD36 and ACC, as a major factors in
lipogenesis, significantly down-regulated by treatment with
KBH-1, whereas, the expression level of ACOX1, CPT-1
and PPARα, as a major factors in lipolysis, was elevated in
a dose-dependent manner. Similarly, the phosphorylation
of adenosine monophosphate-activated protein kinase
(AMPK) and ACC proteins also increased after treatment
with KBH-1 (Fig. 1c). These results indicate that KBH-1
improves fatty acid catabolism at the transcriptional level
by regulating the expression of lipogenic genes and
proteins.
KBH-1 reduces hepatic steatosis in an HFD-induced
obesity model
We investigated the effect of KBH-1 on hepatic steatosis.
First, we analyzed the body weight (Fig. 2a) and body
weight gain (Additional file 2: Figure S2) of HFD-induced
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Fig. 1 Effect of KBH-1 on lipid accumulation and the activation of lipogenic enzymes in HepG2 cells. HepG2 cells cultured in DMEM/F12 supplemented
with 10% fetal bovine serum, then exposed to a mixture for FFA (oleic acid/palmitic acid at 2:1) at a final concentration of 1 mM for 24 h, and the effect
of various concentrations of KBH-1 (10–90 μg/ml) was monitored. (a) Fat droplets in cells were stained with Oil Red O dye. (b) The FFA-induced
phosphorylation of AMPK and ACC was measured using SDS-PAGE and immunoblotting. ACC, AMPK, and β-actin were used for normalization (n = 3).
(c) The FFA-induced mRNA expression of major lipogenic transcription factors (SREBP-1c, SCD-1, CD36, ACC, ACOX1, CPT-1 and PPARα) was analyzed
by quantitative real-time PCR. The results are expressed as a relative density after normalization to the β-actin mRNA level. The data are expressed as
the mean ± SEM. Significant differences from each control (no KBH-1 treatment) are indicated by **p < 0.001
Fig. 2 Effect of KBH-1 on hepatic steatosis of the HFD-induced obesity model. Animals were subdivided into 5 groups: ND, HFD, PC (treated with
200 mg/kg of green tea extract), KBH-1 150 mg/kg, and KBH-1 300 mg/kg. (a) The body weight change of each group in an HFD-induced obesity
model. (b) Representative hematoxylin-eosin staining. (c) The changes of hepatic TG and TC and liver weight. The data are expressed as the
mean ± SEM. Significant differences from the HFD group are indicated by *p < 0.05 or **p < 0.001
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rats. Rats in the KBH-1 group exhibited a significant de-
crease in body weight and body weight gain. HFD-
induced rats exhibited a significant increase in the level of
GPT and LDL-C, and KBH-1 suppressed the levels of
GPT, LDL-C, and TG (Additional file 3: Figure S1). Al-
though the extent of hepatocytes with visible lipid accu-
mulation weakly caused HFD-induced hepatic steatosis,
and KBH-1 at a concentration of 150 and 300 mg/kg sig-
nificantly improved hepatic steatosis, including steatosis
scoring and hepatic TC (Fig. 2b-c).
KBH-1 suppressed lipogenesis in hepatic steatosis
To identify the molecular mechanism with regard to the
inhibitory effect of KBH-1 on hepatic steatosis, we investi-
gated the effect on the activation of AMPK, ACC and
PPARγ proteins or the expression of SREBP-1c, ACC and
3-hydroxy-3-methylglutaryl CoA reductase (HMGCR)
genes. As shown in Fig. 3a, KBH-1 not only up-regulated
the phosphorylation level of AMPK and ACC, as the
kinase inhibited hepatic lipogenesis, but also inhibited
the expression of PPARγ protein associated with the in-
creased expression of lipogenic genes and hepatic TG
accumulation [41, 42]. Moreover, KBH-1 concentration-
dependently suppressed the expression of SREBP-1c, ACC
and HMGCR genes as a major factor in adipogenesis,
which promotes fat accumulation in the liver [43] (Fig. 3b).
In addition, to determine the effect of KBH-1 on lipid per-
oxidation and inflammatory cytokines in the steatotic liver,
we assessed serum and hepatic malondialdehyde (MDA),
tumor necrosis factor (TNF)-α, and IL-1β. As a result,
KBH-1 significantly inhibited serum and hepatic MDA,
whereas green tea extract, as a positive control, had no
direct effect. KBH-1 also dose-dependently suppressed the
TNF-α and IL-1β released from the steatotic liver.
KBH-1 improves the leptin resistance of the
hypothalamus in the HFD-induced obesity model
Next, we investigated the effect of KBH-1 on the leptin
resistance of the hypothalamus and its possible molecu-
lar mechanism. First, in HFD-induced obesity rats, we
assessed the serum leptin level and the feed efficiency
ratio. KBH-1 suppressed the serum leptin level of the
HFD group increased in comparison with the normal
diet (ND) group; similarly, the feed efficiency ratio was
decreased (Fig. 4a). Therefore, we investigated the effect
of KBH-1 on the phosphorylation of ERK, AKT and
AMPK was down-regulated by leptin resistance in hypo-
thalamus. KBH-1 significantly activated the phosphoryl-
ation of ERK and AMPK in a concentration-dependent
manner, whereas AKT phosphorylation was non-
significantly activated (Fig. 4b).
KBH-1 alleviates the resistance of leptin-mediated signal-
ing in primary cultured cortical neuron cells
In primary cultured cortical neuron cells, we confirmed
the alleviated effect of KBH-1 on leptin resistance. In
leptin-resistant neurons induced by FFA, the activation
of leptin-mediated signals, such as AMPK, Ras, cRaf,
ERK, STAT3 and JAK2, was down-regulated. KBH-1 sig-
nificantly improved the phosphorylation of AMPK, cRaf,
ERK, STAT3 and JAK2 in cortical neuron cells treated
with leptin for 15 min (Fig. 5b). Although the alleviation
effect of KBH-1 in cortical neuron cells treated with lep-
tin for 30 min was weak, KBH-1 significantly up-
regulated the phosphorylation of AMPK, Raf, ERK and
JAK2. These findings indicate that KBH-1 can be used
to alleviate the leptin resistance of primary cultured cor-
tical neuron cells in a manner independent of cytotox-
icity (Fig. 5a).
Fig. 3 Anti-lipogenic effect of KBH-1 on hepatic steatosis. (a) Liver tissue was homogenized and the lysates were subjected to western blotting
for AMPK, ACC phosphorylation and PPARγ expression. (b). Liver tissue was homogenized and SREBP-1c, ACC and HMGCR were analyzed by
quantitative real-time PCR. (c) Serum and hepatic MDA, TNFα and IL-1 β was measured with a commercial TBAR assay kit and ELISA kit. The data
are expressed as the mean ± SEM. Significant differences from the HFD group are indicated by *p < 0.05 or **p < 0.001
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Standardization of KBH-1 and its standard compounds
In HPLC analysis, KBH-1 was analyzed to include six
standard compounds: quercitrin, onji-saponin B, BDMC,
DMC, curcumin and sauchinone (Fig. 6a). Thus, to deter-
mine the mechanism of activation, we examined the level
of triglycerides (TGs) in HepG2 cells. The results showed
that onji-saponin B, BDMC, DMC, curcumin and sauchi-
none significantly decreased TG levels; among these active
compounds, onji-saponin B and curcumin were potently
suppressed at a concentration greater than 10 μM (Fig. 6b).
Discussion
The present study shows the effect of KBH-1 in the
treatment of steatosis and liver and accompanying leptin
resistance in the hypothalamus through continuous feed-
ing with a HFD for up to 15 weeks. We showed that the
HFD group increased the lipid accumulation in liver and
lowered the sensitivity of leptin-mediated signals in the
hypothalamus in comparison with those fed with ND.
We demonstrated that KBH-1, as an herbal composition
of Polygala tenuifolia, Curcuma longa, and Saururus chi-
nensis extracts, improved hepatic steatosis and leptin re-
sistance in a HFD-induced obesity model through the
increase of AMPK phosphorylation and the up-regulation
of leptin-mediated signals. Although further studies, in-
cluding clinical trials, are required, KBH-1 may be used as
a functional food supplement to manage obesity. Pres-
ently, KBH-1 is examining the clinical trials based on no
Fig. 4 Effect of KBH-1 on the leptin resistance of the hypothalamus. (a) Hypothalamus tissue was homogenized and (A) serum leptin was measured with
an ELISA kit. The feed efficiency ratio (%) was calculated as weight gain/food intake × 100. (b) The phosphorylation of ERK, AKT and AMPK was measured
using western blotting. The data are expressed as the mean ± SEM. Significant differences from the HFD group are indicated by *p< 0.05 or **p< 0.001
Fig. 5 Effect of KBH-1 on leptin-resistant cortical neuron cells. Cells were cultured in neurobasal medium supplemented with 2% B27, 0.5 mM L-glutamine,
and 25 μM glutamate. After 24 h, the culture medium was replaced with neurobasal medium without glutamate. For the resistance experiments, primary
neurons were pretreated with 0.5 mM FFA (oleic acid:palmitic acid = 2:1) overnight prior to leptin treatment. For treatment studies, neurons were treated
with KBH-1 for 1 h, then treated with 10 nM leptin. (a) Cell viability was determined by the CCK assay. (b) The activation of AMPK, RAS, cRaf, ERK, STAT3
and JAK2 were measured using SDS-PAGE and immunoblotting. β-actin was used for normalization (c, n = 3). The data are expressed as the mean ± SEM.
Significant differences from each control (no KBH-1 treatment) are indicated by *p< 0.05 or **p< 0.001
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observable adverse effect level resulted from the subacute
toxicity test.
NAFLD is considered to be the insulin resistance or the
hepatic component of metabolic syndrome, as it increases
with obesity and type 2 diabetes mellitus [44]. In previous
studies, obesity was shown to be associated with higher
levels of leptin in serum and hepatic steatosis after lipid
accumulation [45]. Therefore, our study shows that KBH-
1 inhibited lipid accumulation by up-regulating AMPK
phosphorylation; moreover, we determined the effect of
the major factor genes in lipogenesis and lipolysis in vitro
(Fig. 1). Our results showed that KBH-1 suppressed the
mRNA expression of SREBP-1c, SCD-1, CD36 and ACC
and increased the mRNA expression of ACOX1, CPT-1
and PPARα, which are the primary enzymes in lipogenesis.
These results indicated that the anti-lipogenic effect of
KBH-1 occurred at the transcriptional level, as SREBP-1
and PPARα, regulators of lipogenesis and lipolysis,
respectively, positively modulate lipid metabolism by in-
ducing the expression of target genes that encode rate-
limiting enzymes, such as ACC, and up-regulating the ex-
pression of the genes involved in the transport and oxida-
tion of fatty acids, such as CPT-1 and CD36 [46].
Similarly, in an in vivo hepatic steatosis model caused by
obesity, KBH-1 not only suppressed the increase of body
weight and body weight gain but also inhibited the in-
creased the steatosis score and level of hepatic TC (Fig. 2).
In lipid metabolism, AMPK, as a key regulator in lipid me-
tabolism, has been well-known to modulate cholesterol
synthesis, hepatic fatty acids, and fatty acid oxidation [47].
Importantly, AMPK phosphorylation suppresses major
factors in lipogenesis, such as SREBP-1 and HMGCR [48].
KBH-1 significantly increased the AMPK protein inhibited
by HFD in liver and also elevated ACC expression, which
is a marker of AMPK activation and a modulator in the
synthesis and oxidation of fatty acids (Fig. 3) [49]. KBH-1
Fig. 6 HPLC profile of KBH-1 and identification of active compound. The HPLC chromatogram of the six standard compounds was monitored at
280 nm. Black, green and red lines represent KBH-1 used in vitro, KBH-1 used in vivo with diluting agent and a mixture of six single compounds
(a). HepG2 cells cultured in DMEM/F12 supplemented with 10% fetal bovine serum, then exposed to a mixture for FFA (oleic acid/palmitic acid at 2:1)
at a final concentration of 1 mM for 24 h, and the effect of various concentrations (1-20 μg/ml) of six standard compounds (quercitrin, onji-saponin B,
BDMC, DMC, curcumin and sauchinone) was monitored. (b) The TG level in cells was stained with Adipore. The data are expressed as the mean ± SEM.
Significant differences from each control (no KBH-1 treatment) are indicated by *p < 0.05 or **p < 0.001
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significantly suppressed the phosphorylation of PPARγ,
which is a transcription factor of TG synthesis and the
master regulator of adipogenesis [50]. In accordance with
these results, the mRNA expression of SREBP-1, ACC and
HMGCR was suppressed by treatment with KBH-1
(Fig. 3). In addition, KBH-1 significantly inhibited the
serum and hepatic levels of MDA, TNFα, and IL-1β, the
last of which is a lipid peroxidation factor and inflamma-
tory cytokines released from steatotic liver (Fig. 3) [51].
Obesity causes leptin resistance in the hypothalamus ac-
companied by hepatic steatosis in the liver. Leptin resist-
ance down-regulated the phosphorylation of the leptin-
mediated signals, such as ERK, AKT, and AMPK [52].
When leptin resistance in the hypothalamus was caused
by obesity, the level of serum leptin and the feed efficiency
ratio was increased [53]. KBH-1 not only suppressed the
leptin level and feed efficiency ratio but also enhanced the
activation of ERK, AKT and AMPK proteins. These results
show that KBH-1 may be used to improve the leptin re-
sistance in the hypothalamus caused by obesity (Fig. 4).
Therefore, in addition, we identified the possible mechan-
ism of KBH-1 in primary cultured cortical neuron cells
pre-treated with FFA in vitro.
In accordance with the results of HFD-induced obesity
in vivo, KBH-1 significantly up-regulated the activation
of leptin-mediated signals, including AMPK and JAK2,
in a time-dependent manner (Fig. 5b). These results in-
dicate that KBH-1 can be used to alleviate the leptin re-
sistance of cortical neuron cells, which was not due to
cytotoxicity (Fig. 5a).
In addition, to standardize KBH-1, we detected six stand-
ard compounds, including quercitrin, onji-saponin B,
BDMC, DMC, curcumin and sauchinone, using HPLC ana-
lysis (Fig. 6a). Next, to identify the active compound of
KBH-1, we investigated the level of TG in hepG2 stimulated
by FFA. As a result, onji-saponin B and curcumin potently
suppressed the level of TG stimulated by FFA (Fig. 6b).
Conclusion
We have obtained experimental evidence that KBH-1, in-
cluding onji-saponin B and curcumin, improves the hepatic
steatosis and leptin resistance of hypothalamus in an HFD-
induced obesity rat model by up-regulating the activation of
AMPK and suppressing the expression of PPARγ in the liver
and enhancing the leptin-mediated signals in the hypothal-
amus. Therefore, we judiciously expect that KBH-1 extract
may be used as a functional food supplement or as a pre-
ventive agent to manage the complication of obesity.
Additional file
Additional file 1: Table S1. Blood chemical analysis on high-fat diet
(HFD)-induced obesity rat model . HFDinduced rats show significant
increase the level of GPT and LDL-C, and KBH-1 suppressed the level of
GPT, LDL-C, and TG. (DOCX 16 kb)
Additional file 2: Figure S2. Effect of KBH-1 on hepatic steatosis of
HFD-induced obesity model. Animals were subdivided into 5 groups:
ND, HFD, PC (treated with 200mg/kg of green tea extract), KBH-1
150mg/kg, and KBH-1 300 mg/kg. The body weight change of each
group on HFD-induced obesity model. Data are expressed as the mean
± SEM. Significant differences from HFD group are indicated by *p < 0.05,
**p < 0.01, or ***p < 0.005. (DOCX 55 kb)
Additional file 3: Figure S1. Effect of KBH-1 on cell viability and lipid
accumulation. HepG2 cells was routinely cultured in DMEM/F12. The cells
were treated with various concentration (0-90 μg/ml) of Saururus
chinensis (SC), Curcuma longa (CL), Polygala tenuifolia (PT) or KBH-1
extracts for 6 h, then exposed to a mixture for FFA (oleic acid/palmitic
acid at 2:1). (A) Intracellular triglyceride contents were examined using
the AdipoRed Assasy kit. (B) Cell viability was determined by the CCK
assay. The results were confirmed by three independent experiments,
which were each conducted in triplicate. Data are expressed as the mean
± SEM. Significant differences from control (0 μg/ml) are indicated by
*p < 0.05, or ***p < 0.005. (DOCX 42 kb)
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